Insulin resistance after precocious pubarche: Relation to PAI-1-675 4G/5G polymorphism, and opposing influences of prenatal and postnatal weight gain

Clinical Endocrinology

Volumn 67, Issue 4, 2007, Pages 493-499

  López Bermejo, Abel ^a   Casano Sancho, Paula ^b   Petry, Clive J ^c   Jaramillo, Adriana M ^b   Rodríguez González, Francesc Xavier ^a   Dunger, David B ^c   De Zegher, Francis ^d   Ibáñez, Lourdes ^b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENOTYPE; HOMEOSTASIS; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PERINATAL PERIOD; PRECOCIOUS PUBERTY; PRENATAL PERIOD; PRIORITY JOURNAL; WEIGHT GAIN;

ADOLESCENT; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHILD; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LINEAR MODELS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PUBERTY, PRECOCIOUS; WEIGHT GAIN;

EID: 34548694309     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02914.x     Document Type: Article

References (49)

1. Ibáñez, L., Potau, N., Francois, I. de Zegher, F. (1998) Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. Journal of Clinical Endocrinology and Metabolism, 83, 3558 3562.
2. Ibáñez, L., Valls, C., Potau, N., Marcos, M.V. de Zegher, F. (2001) Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clinical Endocrinology, 55, 667 672.
3. Ibáñez, L., Valls, C., Potau, N., Marcos, M.V. de Zegher, F. (2000) Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. Journal of Clinical Endocrinology and Metabolism, 85, 3526 3530.
4. Ibáñez, L., Valls, C., Ferrer, A., Marcos, M.V., Rodriguez-Hierro, F. de Zegher, F. (2001) Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 86, 3595 3598.
5. Ibáñez, L., Ferrer, A., Ong, K., Amin, R., Dunger, D. de Zegher, F. (2004) Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. Journal of Pediatrics, 144, 23 29.
6. Ibáñez, L., Valls, C., Marcos, M.V., Ong, K., Dunger, D.B. De Zegher, F. (2004) Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. Journal of Clinical Endocrinology and Metabolism, 89, 4331 4337.
7. Sprengers, E.D. Kluft, C. (1987) Plasminogen activator inhibitors. Blood, 69, 381 387.
8. Kohler, H.P. Grant, P.J. (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. New England Journal of Medicine, 342, 1792 1801.
9. Byberg, L., McKeigue, P.M., Zethelius, B. Lithell, H.O. (2000) Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia, 43, 54 60.
10. Sampson, M., Kong, C., Patel, A., Unwin, R. Jacobs, H.S. (1996) Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology, 45, 623 629.
11. Juhan-Vague, I., Vague, P., Alessi, M.C., Badier, C., Valadier, J., Aillaud, M.F. Atlan, C. (1987) Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes & Metabolism, 13, 331 336.
12. Juhan-Vague, I., Roul, C., Alessi, M.C., Ardissone, J.P., Heim, M. Vague, P. (1989) Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients - relationship with plasma insulin. Thrombosis and Haemostasis, 61, 370 373.
13. Samad, F., Pandey, M., Bell, P.A. Loskutoff, D.J. (2000) Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Molecular Medicine, 6, 680 692.
14. Folsom, A.R., Qamhieh, H.T., Wing, R.R., Jeffery, R.W., Stinson, V.L., Kuller, L.H. Wu, K.K. (1993) Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis, Thrombosis and Vascular Biology, 13, 162 169.
15. Ehrmann, D.A., Schneider, D.J., Sobel, B.E., Cavaghan, M.K., Imperial, J., Rosenfield, R.L. Polonsky, K.S. (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 2108 2116.
16. Velazquez, E.M., Mendoza, S.G., Wang, P. Glueck, C.J. (1997) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism, 46, 454 457.
17. Lopez-Alemany, R., Redondo, J.M., Nagamine, Y. Munoz-Canoves, P. (2003) Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. European Journal of Biochemistry, 270, 814 821.
18. Ma, L.J., Mao, S.L., Taylor, K.L., Kanjanabuch, T., Guan, Y., Zhang, Y., Brown, N.J., Swift, L.L., McGuinness, O.P., Wasserman, D.H., Vaughan, D.E. Fogo, A.B. (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes, 53, 336 346.
19. Festa, A., D'Agostino, R. Jr., Tracy, R.P. Haffner, S.M. (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 51, 1131 1137.
20. Dawson, S.J., Wiman, B., Hamsten, A., Green, F., Humphries, S. Henney, A.M. (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. Journal of Biological Chemistry, 268, 10739 10745.
21. Eriksson, P., Kallin, B., van T., Hooft, F.M., Bavenholm, P. Hamsten, A. (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proceedings of the National Academy of Sciences of the USA, 92, 1851 1855.
22. Lopes, C., Dina, C., Durand, E. Froguel, P. (2003) PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia, 46, 1284 1290.
23. Leander, K., Wiman, B., Hallqvist, J., Sten-Linder, M. de Faire, U. (2003) PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP). Thrombosis and Haemostasis, 89, 1064 1071.
24. Juhan-Vague, I., Morange, P.E., Frere, C., Aillaud, M.F., Alessi, M.C., Hawe, E., Boquist, S., Tornvall, P., Yudkin, J.S., Tremoli, E., Margaglione, M., Di Minno, G., Hamsten, A. Humphries, S.E. (2003) The plasminogen activator inhibitor-1-675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. Journal of Thrombosis and Haemostasis, 1, 2322 2329.
25. Hoffstedt, J., Andersson, I.L., Persson, L., Isaksson, B. Arner, P. (2002) The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia, 45, 584 587.
26. Mansfield, M.W., Stickland, M.H. Grant, P.J. (1995) Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thrombosis and Haemostasis, 74, 1032 1034.
27. Ridker, P.M., Hennekens, C.H., Lindpaintner, K., Stampfer, M.J. Miletich, J.P. (1997) Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation, 95, 59 62.
28. Anderson, J.L., Muhlestein, J.B., Habashi, J., Carlquist, J.F., Bair, T.L., Elmer, S.P. Davis, B.P. (1999) Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. Journal of the American College of Cardiology, 34, 1778 1783.
29. YeZ., Liu, E.H., Higgins, J.P., Keavney, B.D., Lowe, G.D., Collins, R. Danesh, J. (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet, 367, 651 658.
30. Elbaz, A., Cambien, F. Amarenco, P. (2001) Plasminogen activator inhibitor genotype and brain infarction. Circulation, 103, e13 14.
31. Roest, M., van der Schouw, Y.T., Banga, J.D., Tempelman, M.J., de Groot, P.G., Sixma, J.J. Grobbee, D.E. (2000) Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation, 101, 67 70.
32. Bensen, J.T., Hsu, F.C., Brown, W.M., Sutton, B.S., Norris, J.M., Tracy, R.P., Jenny, N.S., Saad, M.F., Haffner, S., Bowden, D.W. Langefeld, C.D. (2004) Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS family study. Human Heredity, 57, 128 137.
33. Bouchard, L., Mauriege, P., Vohl, M.C., Bouchard, C. Perusse, L. (2005) Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause, 12, 136 143.
34. Yamada, Y., Izawa, H., Ichihara, S., Takatsu, F., Ishihara, H., Hirayama, H., Sone, T., Tanaka, M. Yokota, M. (2002) Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. New England Journal of Medicine, 347, 1916 1923.
35. Ibáñez, L., Aulesa, C., Potau, N., Ong, K., Dunger, D.B. de Zegher, F. (2002) Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatric Research, 51, 244 248.
36. Mermejo, L.M., Elias, L.L., Marui, S., Moreira, A.C., Mendonca, B.B. de Castro, M. (2005) Refining hormonal diagnosis of type II, 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. Journal of Clinical Endocrinology and Metabolism, 90, 1287 1293.
37. New, M.I., Lorenzen, F., Lerner, A.J., Kohn, B., Oberfield, S.E., Pollack, M.S., Dupont, B., Stoner, E., Levy, D.J., Pang, S. Levine, L.S. (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. Journal of Clinical Endocrinology and Metabolism, 57, 320 326.
38. Vicedo, E.M., Mataró, D., Martínez, S., Gavaldá, L. Sabriá, J. (1998) Neonatal weight charts for the population served by Dr Josep Trueta University Hospital at Girona. Progresos de Obstetricia y Ginecología, 41, 215 220.
39. de la Puente, M.L., Canela, J., Alvarez, J., Salleras, L. Vicens-Calvet, E. (1997) Cross-sectional study of the child and adolescent population of Catalonia. Annals of Human Biology, 24, 435 452.
40. Ibáñez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D. de Zegher, F. (2003) Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 88, 2600 2606.
41. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
42. Diamanti-Kandarakis, E., Palioniko, G., Alexandraki, K., Bergiele, A., Koutsouba, T. Bartzis, M. (2004) The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. European Journal of Endocrinology, 150, 793 798.
43. Tarkun, I., Canturk, Z., Arslan, B.C., Turemen, E. Tarkun, P. (2004) The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrine Journal, 51, 467 472.
44. Orio, F. Jr., Palomba, S., Cascella, T., Tauchmanova, L., Nardo, L.G., Di Biase, S., Labella, D., Russo, T., Savastano, S., Tolino, A., Zullo, F., Colao, A. Lombardi, G. (2004) Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reproductive Biomedicine Online, 9, 505 510.
45. Juhan-Vague, I., Alessi, M.C. Morange, P.E. (2000) Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Annals of Medicine, 32 (Suppl. 1 78 84.
46. Atiomo, W.U., Hilton, D., Fox, R., Lee, D., Shaw, S., Friend, J., Wilkin, T.J. Prentice, A.G. (2000) Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries. Gynecological Endocrinology, 14, 162 168.
47. San Millan, J.L., Corton, M., Villuendas, G., Sancho, J., Peral, B. Escobar-Morreale, H.F. (2004) Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. Journal of Clinical Endocrinology and Metabolism, 89, 2640 2646.
48. Walch, K., Grimm, C., Huber, J.C., Nagele, F., Kolbus, A. Hefler, L.A. (2005) A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 123, 77 81.
49. Glueck, C.J., Sieve, L., Zhu, B. Wang, P. (2006) Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor-1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism, 55, 345 352.